They also say that research and development by private pharmaceutical companies have tended to neglect diseases afflicting poorer countries.
Ka väidavad nad, et ravimeid tootvad erakompaniid kipuvad uurimistöö ja tootearengu vallas jätma kõrvale vaesemate maade vajadused.